Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Intra-Peritoneal Cisplatin Combined with Intravenous Paclitaxel in Optimally Debulked Stage 3 Ovarian Cancer Patients: An Izmir Oncology Group Study

  • Unal, Olcun Umit (Department of Internal Medicine, Ataturk University) ;
  • Yilmaz, Ahmet Ugur (Department of Internal Medicine, Division of Medical Oncology, Izmir University, Medicine Faculty) ;
  • Yavuzsen, Tugba (Department of Medical Oncology, Dokuz Eylul University, Oncology Institute) ;
  • Akman, Tulay (Department of Medical Oncology, Dokuz Eylul University, Oncology Institute) ;
  • Ellidokuz, Hulya (Department of Preventive Oncology, Dokuz Eylul University, Oncology Institute)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The advantage of intra-peritoneal (IP) chemotherapy (CT) in the initial management of ovarian cancer after cytoreductive surgery is well known. The feasibility and toxicity of a treatment regimen with an IP + intravenous CT (IPIVCT) for optimally debulked stage III ovarian cancer were here evaluated retrospectively. Materials and Methods: A total of 30 patients were treated in our institution between October 2006 and February 2011. Patients received IV paclitaxel $175mg/m^2$ over 3 hours followed by IP cisplatin $75mg/m^2$ on day 1; they also received IP paclitaxel $60mg/m^2$ on day 8. They were also scheduled to receive 6 courses of CT every 21 days. Results: The median age of the patients was 55 years (35-77), and the majority had papillary serous ovarian cancer (63.3%). The patients completed a total of 146 cycles of IPIVCT. Twenty-eight were able to receive at least three cycles of IPIVCT and 18 (60%) completed the scheduled 6 cycles. Two patients discontinued the IPIVCT because of toxicity of chemotherapy agents and 6 had to stop treatment due to intolerable abdominal pain during IP drug administration, obstruction and impaired access. Grade 3/4 toxicities included neutropenia (6 patients; 20%), anemia (2 patients; 6.7%) and nausea-vomiting (2 patients; 6.7%). Doses were delayed in 12 cycles (8%) for neutropenia (n=6), thrombocytopenia (n=3) and elevated creatinine (n=3). Drug doses were not reduced. The median duration of progression-free survival (PFS) was 47.7 months (95%CI, 38.98-56.44) and overall survival (OS) was 51.7 months (95%CI, 44.13-59.29). Two and five-year overall survival rates were 75.6 % and 64.8%, respectively. Conclusions: IPIVCT is feasible and well-tolerated in this setting. Its clinically proven advantages should be taken into consideration and more efforts should be made to administer IPIVCT to suitable patients.

Keywords

References

  1. Alberts DS, Liu PY, Hannigan EV, et al (1996). Intra-peritoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med, 335, 1950-5. https://doi.org/10.1056/NEJM199612263352603
  2. Armstrong DK, Bundy L, Wenzel HQ, et al (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med, 354, 34-43. https://doi.org/10.1056/NEJMoa052985
  3. Arun-Muthuvel V, Jaya V (2014). Pre-operative evaluation of ovarian tumors by risk of malignancy index, CA125 and ultrasound. Asian Pac J Cancer Prev, 15, 2929-32. https://doi.org/10.7314/APJCP.2014.15.6.2929
  4. Barlin JN, Dao F, Bou Zgheib N, et al (2012). Progressionfree and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol, 125, 621-4. https://doi.org/10.1016/j.ygyno.2012.03.027
  5. Chumworathayi B (2013). Personalized cancer treatment for ovarian cancer. Asian Pac J Cancer Prev, 14, 1661-4. https://doi.org/10.7314/APJCP.2013.14.3.1661
  6. Dedrick RL, Flessner MF(1997). Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst, 89, 480-7. https://doi.org/10.1093/jnci/89.7.480
  7. Fujiwara K, Sakuragi N, Suzuki S, et al (2003). First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of longterm follow-up. Gynecol Oncol, 90, 637-43. https://doi.org/10.1016/S0090-8258(03)00377-9
  8. Gaemmaghami F, Yousefi Z, Gilani M, et al (2011). Role of Appropriate Surgery in Survival of Patients with Epithelial Ovarian Cancer. Asian Pacific J Cancer Prev, 12, 253-7.
  9. Gray HJ, Shah CA, Swensen RE, et al (2010). Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. Gynecol Oncol, 116, 340-4. https://doi.org/10.1016/j.ygyno.2009.10.054
  10. Kokanali MK, Guzel AI, Erkilinc S, et al (2014). Risk factors for appendiceal metastasis with epithelial ovarian cancer. Asian Pac J Cancer Prev, 15, 2689-92. https://doi.org/10.7314/APJCP.2014.15.6.2689
  11. Koo YJ, Kim JE, Kim YH, et al (2014). Comparison of laparoscopy and laparotomy for the management of earlystage ovarian cancer: surgical and oncological outcomes. J Gynecol Oncol, 25, 111-7 https://doi.org/10.3802/jgo.2014.25.2.111
  12. Liu XH, Man YN, Wu XZ (2014). Recurrence season impacts the survival of epithelial ovarian cancer patients. Asian Pac J Cancer Prev, 15, 1627-32. https://doi.org/10.7314/APJCP.2014.15.4.1627
  13. Markman M, Bundy BN, Alberts DS, et al (2001). Phase III trial of standart dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intra-peritoneal cisplatin in small volume stage III ovarian carcinoma: an Intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group. J Clin Oncol, 19, 1001-7.
  14. Nicoletto MO, Dalla Palma M, Donach ME, et al (2010). Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer. Tumori, 96, 918-25.
  15. Oaknin A, Roda D, Gonzalez-Martin A, et al (2011). Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study. Int J Gynecol Cancer, 21, 1048-55. https://doi.org/10.1097/IGC.0b013e31821ee777
  16. Ozols RF, Bundy BN, Fowler J, et al (1999). Randomized phase III study of cisplatin (CIS) /paclitaxel (PAC) versus carboplatin (CARBO) /PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158). Proceedings of the Annual Meeting of the American Society Clin Oncol, 18, 1373.
  17. Piccart MJ, Floquet A, Scarfone G, et al (2003). Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer, 13, 196-203. https://doi.org/10.1111/j.1525-1438.2003.13360.x
  18. Sarkar M, Konar H, Raut D (2013). Clinico-pathological features of gynecological malignancies in a tertiary care hospital in eastern India: importance of strengthening primary health care in prevention and early detection. Asian Pac J Cancer Prev, 14, 3541-7. https://doi.org/10.7314/APJCP.2013.14.6.3541
  19. Seamon LG, Carlson MJ, Richardson DL, et al (2009). Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer. Int J Gynecol Cancer, 19, 1195-8. https://doi.org/10.1111/IGC.0b013e3181b33d5b
  20. Seigal R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  21. Skaznik-Wikiel ME, Lesnock JL, McBee WC, et al (2012). Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes. Int J Gynecol Cancer, 22, 232-7. https://doi.org/10.1097/IGC.0b013e318234f833
  22. Suprasert P, Chalapati W (2013). Detection of recurrence in a surveillance program for epithelial ovarian cancer. Asian Pac J Cancer Prev, 14, 7193-6. https://doi.org/10.7314/APJCP.2013.14.12.7193
  23. Suprasert P, Manopunya M, Cheewakriangkrai C (2014). Outcomes with single agent LIPO-DOX in platinumresistant ovarian and fallopiantube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience. Asian Pac J Cancer Prev, 15, 1145-8. https://doi.org/10.7314/APJCP.2014.15.3.1145
  24. Walker JL, Armstrong DK, Huang HQ, et al (2006). Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intra-peritoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol, 100, 27-32. https://doi.org/10.1016/j.ygyno.2005.11.013
  25. Weisberger AS, Levine B, Storaasli JP (1955). Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA, 159, 1704-7.
  26. Yen MS, Juang CM, Lai CR, et al (2001). Intraperitoneal cisplatin-based chemotherapy vs intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet, 72, 55-60. https://doi.org/10.1016/S0020-7292(00)00340-4

Cited by

  1. p21-Activated kinase 5 affects cisplatin-induced apoptosis and proliferation in hepatocellular carcinoma cells vol.36, pp.5, 2015, https://doi.org/10.1007/s13277-014-3007-5